Oncolysin SAlternative Names: N901-blocked ricin; N901-BR
Latest Information Update: 25 Nov 1998
At a glance
- Originator ImmunoGen
- Developer Dana-Farber Cancer Institute; ImmunoGen
- Class Immunotoxins; Monoclonal antibodies
- Mechanism of Action Protein synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Small cell lung cancer